EMEA-002919-PIP01-20 - paediatric investigation plan

Sintilimab

Key facts

• Active Substance:
  Sintilimab
• Therapeutic area:
  Oncology
• Decision number:
  P/0139/2021
• PIP number:
  EMEA-002919-PIP01-20
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of lung cancer
• Route(s) of administration:
  All routes of administration
• Contact for public enquiries:

  Eli Lilly & Company Limited

  Tel. [phone]; E-mail: [e-mail]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  16/04/2021

Decision

P/0139/2021 : EMA decision of 16 April 2021 on the granting of a product specific waiver for sintilimab (EMEA-002919-PIP01-20)

Reference Number: EMA/190318/2021